Vestura (Drospirenone 3 mg / Ethinyl Estradiol 0.02 mg) – Evidence‑Based Clinical Guidance

Indications

• Vestura may be prescribed for moderate acne vulgaris in females ≥ 14 years who have attained menarche. 1

Dosing & Missed‑Dose Management

• If a pill is missed, the patient should take it as soon as remembered; if more than one pill is missed, only the most recently missed pill is taken and the regular schedule is continued. 2
• When a pill is missed during the first week, backup contraception (condoms or abstinence) should be used for 7 days. 2
• Consider emergency contraception if ≥ 2 pills are missed in week 1 or if pills were missed late in the previous cycle. 2

Contraindications & High‑Risk Conditions (WHO Category 4)

• Age ≥ 35 years and any amount of smoking. 3
• Prior deep‑vein thrombosis or pulmonary embolism. 3
• Severe uncontrolled hypertension (systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg). 4
• Migraine with focal neurologic symptoms at any age, or migraine without aura in women ≥ 35 years. 4
• History of ischemic heart disease, cerebrovascular accident, or complicated valvular heart disease. 4
• Active viral hepatitis, decompensated cirrhosis, or hepatic tumors (benign or malignant). 4
• Diabetes with end‑organ damage (nephropathy, retinopathy, neuropathy, or vascular disease). 4
• Current breast cancer or other estrogen/progestin‑sensitive malignancies. 4
• Undergoing major surgery requiring prolonged immobilization. 4

Precautions & Safety

Venous Thromboembolism (VTE)

• Drospirenone‑containing combined oral contraceptives increase VTE risk by 50–80 % compared with levonorgestrel‑containing pills; incidence ≈ 10 events per 10 000 woman‑years versus 6 per 10 000 for standard low‑dose COCs. 5
• Background VTE rate in non‑users is 2 events per 10 000 person‑years. 5
• The excess risk is attributed specifically to the drospirenone component. 5
• Immediate discontinuation is advised if signs of thrombosis appear (leg pain/swelling, sudden chest pain, dyspnea, severe headache, visual changes, or focal weakness). 5

Hyperkalemia

• Drospirenone possesses antimineralocorticoid activity; serum potassium should be checked during the first treatment cycle in women taking potassium‑increasing drugs (ACE inhibitors, ARBs, potassium‑sparing diuretics, NSAIDs, heparin). 6
• Large retrospective studies have not shown an increased hyperkalemia risk in healthy women, even when combined with spironolactone. 5
• Routine potassium monitoring is unnecessary in women without risk factors. 5

Cardiovascular Effects

• Drospirenone typically lowers systolic blood pressure by 1–4 mm Hg; in women with baseline systolic ≥ 130 mm Hg, the reduction averages ≈ 8 mm Hg. 7
• One 12‑month study reported mean systolic BP decreasing from 109.2 to 103.4 mm Hg. 5
• The absolute attributable risk for major cardiovascular events (myocardial infarction, stroke) is about 2 events per 10 000 person‑years. 5
• Blood pressure should be measured at baseline and at follow‑up visits. 6

Adverse Effects

• In PMDD trials, menstrual irregularities (breakthrough bleeding/spotting) occurred in 24.9 % of users. 5
• Breakthrough bleeding is most common during the first 2–3 cycles and usually resolves spontaneously. 5
• Persistent bleeding beyond 3 cycles warrants evaluation for pregnancy, sexually transmitted infections, cervical pathology, or drug interactions. 8

Drug Interactions

• Strong CYP3A4 enzyme inducers (e.g., rifampin, griseofulvin) can diminish contraceptive effectiveness; backup contraception should be used. 1
• Tetracycline‑class antibiotics do not reduce contraceptive effectiveness and are safe to co‑administer. 1
• Medications that raise serum potassium (ACE inhibitors, ARBs, potassium‑sparing diuretics, NSAIDs, heparin) require potassium monitoring when used with Vestura. 6

Baseline & Ongoing Monitoring

• Prior to prescribing, obtain a comprehensive medical history and measure blood pressure; pelvic examination and Pap smear are no longer mandatory. [1][6]
• Confirm non‑pregnant status before initiation. 6
• Screen for contraindications such as thrombotic risk factors, liver disease, migraine with aura, and smoking in women ≥ 35 years. [4][3]
• Offer, but do not require, STI screening for sexually active patients. [2][3]
• Schedule a follow‑up visit 1–3 months after start to address adverse effects and adherence. [2][3]
• Re‑measure blood pressure at each follow‑up; assess bleeding patterns every 3 months. [6][5]8

Patient Counseling

• Initiate Vestura on the same day as the clinical visit (“quick start”) for healthy, non‑pregnant adolescents; use backup contraception for the first 7 days. [2][3]
• Acne improvement becomes statistically significant by cycle 3, though patients may notice changes later. 1
• Emphasize consistent daily intake (same time each day) and use reminders (phone alarms, support from family/partner). 2
• Prescribe up to a 1‑year supply to improve continuation rates. 2
• Explain that seven consecutive active pills are required to reliably suppress ovulation. 2
• For nausea, advise taking the tablet with food or at bedtime; symptoms usually resolve within the first few cycles. 5
• Reassure that breakthrough bleeding typically resolves within 2–3 cycles and that adherence verification is key. 5
• Advise immediate medical attention for signs of stroke, myocardial infarction, or new‑onset migraine with aura. 5

Non‑contraceptive Benefits

• Vestura helps regulate menstrual cycles, reduces menorrhagia and associated anemia, and lowers the risk of benign ovarian tumors. 1
• Use is associated with a 29 % reduction in gynecologic malignancies, contributing to an overall decrease in cancer risk. 5
• Significant risk reductions have been observed for colorectal, uterine, and ovarian cancers. 5
• Extended or continuous‑use regimens can treat dysmenorrhea, endometriosis, heavy menstrual bleeding, and cyclically exacerbated conditions such as migraine without aura and epilepsy. 2

Special Populations

• Adolescents: FDA‑approved for females ≥ 14 years who have attained menarche. 1
• Smoking is not a contraindication in women < 35 years. [2][3]
• Safety and efficacy have been demonstrated in the adolescent population. 6
• Lactating women: Vestura may reduce milk production; the World Health Organization recommends avoiding it when possible. 6

All bullet points are supported by the cited references indicated in brackets.

Antimineralocorticoid Action of Drospirenone Counteracts Estrogen‑Induced Sodium Retention

Mechanism of Action

• Drospirenone acts as an aldosterone antagonist at the mineralocorticoid receptor, opposing the sodium‑retaining effect of ethinyl estradiol by decreasing hepatic angiotensinogen production and attenuating activation of the renin‑angiotensin‑aldosterone system, which leads to natriuresis. 9